Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Michael R. Grever
(1)
,
Omar Abdel-Wahab
(2)
,
Leslie A. Andritsos
(1)
,
Versha Banerji
(3)
,
Jacqueline Barrientos
(4)
,
James S. Blachly
(1)
,
Timothy G. Call
(5)
,
Daniel Catovsky
(6)
,
Claire Dearden
(7)
,
Judit Demeter
(8)
,
Monica Else
(6)
,
Francesco Forconi
(9)
,
Alessandro Gozzetti
(10)
,
Anthony D. Ho
(11)
,
James B. Johnston
(3)
,
Jeffrey Jones
(1)
,
Gunnar Juliusson
(12)
,
Eric Kraut
(1)
,
Robert J. Kreitman
(13)
,
Loree Larratt
(14)
,
Francesco Lauria
(10)
,
Gerard Lozanski
(1)
,
Emili Montserrat
(15)
,
Sameer A. Parikh
(5)
,
Jae H. Park
(2)
,
Aaron Polliack
(16)
,
Graeme R. Quest
(17)
,
Kanti R. Rai
(4)
,
Farhad Ravandi
(18)
,
Tadeusz Robak
(19)
,
Alan Saven
(20)
,
John F. Seymour
(21)
,
Tamar Tadmor
(22)
,
Martin S. Tallman
(2)
,
Constantine Tam
(21)
,
Enrico Tiacci
(23)
,
Xavier Troussard
(24, 25)
,
Clive S. Zent
(26)
,
Thorsten Zenz
(27)
,
Pier Luigi Zinzani
(28)
,
Brunangelo Falini
(23)
1
OSU -
The Ohio State University [Columbus]
2 Memorial Sloane Kettering Cancer Center [New York]
3 University of Manitoba [Winnipeg]
4 Hofstra University [Hempstead]
5 Mayo Clinic [Rochester]
6 The institute of cancer research [London]
7 Royal Marsden NHS Foundation Trust
8 Semmelweis University of Medicine [Budapest]
9 University of Southampton
10 Azienda Ospedaliera Universitaria Senese
11 University of Heidelberg, Medical Faculty
12 Skane University Hospital [Lund]
13 NIH - National Institutes of Health [Bethesda, MD, USA]
14 University of Alberta
15 UB - Universitat de Barcelona
16 The Hebrew University Hadassah Medical School
17 University Health Network [Toronto, ON, Canada]
18 The University of Texas M.D. Anderson Cancer Center [Houston]
19 MUL - Medical University of Łódź
20 Scripps Clinic [San Diego, CA, USA]
21 University of Melbourne
22 Technion - Israel Institute of Technology [Haifa]
23 UNIPG - Università degli Studi di Perugia = University of Perugia
24 CHU Caen
25 GPMCND - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques
26 URMC - University of Rochester Medical Center
27 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
28 UNIBO - Alma Mater Studiorum Università di Bologna = University of Bologna
2 Memorial Sloane Kettering Cancer Center [New York]
3 University of Manitoba [Winnipeg]
4 Hofstra University [Hempstead]
5 Mayo Clinic [Rochester]
6 The institute of cancer research [London]
7 Royal Marsden NHS Foundation Trust
8 Semmelweis University of Medicine [Budapest]
9 University of Southampton
10 Azienda Ospedaliera Universitaria Senese
11 University of Heidelberg, Medical Faculty
12 Skane University Hospital [Lund]
13 NIH - National Institutes of Health [Bethesda, MD, USA]
14 University of Alberta
15 UB - Universitat de Barcelona
16 The Hebrew University Hadassah Medical School
17 University Health Network [Toronto, ON, Canada]
18 The University of Texas M.D. Anderson Cancer Center [Houston]
19 MUL - Medical University of Łódź
20 Scripps Clinic [San Diego, CA, USA]
21 University of Melbourne
22 Technion - Israel Institute of Technology [Haifa]
23 UNIPG - Università degli Studi di Perugia = University of Perugia
24 CHU Caen
25 GPMCND - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques
26 URMC - University of Rochester Medical Center
27 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
28 UNIBO - Alma Mater Studiorum Università di Bologna = University of Bologna
Résumé
Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the first-line and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients.